Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,174 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: stem cell infusion Clear all

Conditions: Renal Failure
Interventions: Enriched Hematopoietic Stem Cell Infusion; Biological
Lead sponsor: Talaris Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois • Louisville, Kentucky

Conditions: Myeloma
Interventions: G-CSF, Plerixafor, Apheresis, Melphalan, Stem cell re-infusion, Basiliximab, CliniMACS CD25 microbeads and cell sorter; Drug · Procedure · Device
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma
Interventions: dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone, allogeneic hematopoietic stem cell transplantation, CliniMACS; Drug · Biological · Other + 2 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 3
States / cities: San Diego, California • Memphis, Tennessee • Fort Worth, Texas

Conditions: Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome
Interventions: Biospecimen Collection, Busulfan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Emapalumab, Fludarabine, Hematopoietic Cell Transplantation, Melphalan, Multigated Acquisition Scan, Mycophenolate Mofetil, Questionnaire Administration, Tacrolimus; Procedure · Drug · Biological + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Acute Graft vs Host Disease
Interventions: Recombinant Human Interleukin-22 IgG2-Fc (F-652), Systemic Corticosteroids; Drug
Lead sponsor: EVIVE Biotechnology; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Duarte, California • New York, New York • Houston, Texas

Conditions: Lymphoma
Interventions: Lenalidomide, Vorinostat, Gemcitabine, Busulfan, Melphalan, Rituximab, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Enoxaparin, Stem Cell Transplant, Palifermin; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts
Interventions: Dilanubicel, Cyclophosphamide, Fludarabine, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation, Laboratory Biomarker Analysis, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Multigated Acquisition Scan, Electrocardiography, Computed Tomography; Biological · Drug · Radiation + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 10 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT), Primary Immunodeficiency Disorders (PID)
Interventions: Norovirus -specific T-cell (NST) therapy; Biological
Lead sponsor: Children's National Research Institute; Other
Eligibility: 3 Months to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland

Conditions: Graft-Versus-Host Disease
Interventions: Prochymal®; Drug
Lead sponsor: Mesoblast, Inc.; Industry
Eligibility: 18 Years to 70 Years
U.S. locations: 3
States / cities: Beech Grove, Indiana • Boston, Massachusetts • New York, New York

Conditions: Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions: Brentuximab Vedotin, Hematopoietic Cell Transplantation, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration; Drug · Procedure · Biological + 1 more
Lead sponsor: Emory University; Other
Eligibility: 12 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Acute Leukemia, Acute Lymphoblastic Lymphoma
Interventions: 200 cGy or 400 cGy total body irradiation (TBI); Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Not listed
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Interventions: Blinatumomab, Pembrolizumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: La Jolla, California • Charleston, South Carolina • Greenville, South Carolina

Conditions: Infection
Interventions: Multivirus Specific T cells; Biological
Lead sponsor: AlloVir; Industry
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)
Interventions: Omidubicel (former CordIn), Miltenyi CliniMACS(R) CD34 Reagent System; Biological · Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 4 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions: Ara-C, Mitoxantrone, Etoposide; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 10 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cerebral Adrenoleukodystrophy (CALD)
Interventions: Lenti-D Drug Product (eli-cel); Genetic
Lead sponsor: Genetix Biotherapeutics Inc.; Industry
Eligibility: Up to 17 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • Minneapolis, Minnesota

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Interferon gamma-1b, Donor Leukocyte Infusion (DLI); Drug · Biological
Lead sponsor: Sawa Ito, MD; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: St Louis, Missouri • Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions: G-CSF plus plerixafor, rituximab; Drug · Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: BK Virus Infection
Interventions: Viralym-B; Biological
Lead sponsor: AlloVir; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease
Interventions: Lung Spheroid Stem Cells 100 million, Lung Spheroid Stem Cells 200 million; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Multiple Myeloma
Interventions: myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D; Device · Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Acute Leukemia (Category)
Interventions: HSV-Tk, T-cell depleted or T-cell replete strategies; Genetic · Other
Lead sponsor: AGC Biologics S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 3
States / cities: Chicago, Illinois • St Louis, Missouri • Hackensack, New Jersey

Conditions: Cerebral Palsy
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 3 Years and older · Male only
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Glioblastoma Multiforme
Interventions: MGMTP140K-encoding retroviral vector, O6-benzylguanine, temozolomide, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Other + 2 more
Lead sponsor: Stanton Gerson MD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion

Stem Cell Transplantation for Patients With Multiple Myeloma

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts

Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant

Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)

Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)

Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy

BG & TMZ Therapy of Glioblastoma Multiforme